Abstract
The introduction of the atypical antipsychotic agents clozapine and risperidone signalled a significant advance in the management of patients with schizophrenia. Several other newer atypical agents have recently entered the market including sertindole, olanzapine and quetiapine and others are waiting in the wings to vie for market share. These newer agents have focused attention on the treatment of negative symptoms, tolerability issues and the potential to treat co-morbid conditions in patients with schizophrenia. The most recent developments with these atypical antipsychotics were presented at the 10th Congress of the European College of Neuropsychopharmacology [Vienna, Austria; September 1997].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
